Short-course subcutaneous treatment with birch pollen allergoids greatly improves symptom and medication scores in birch allergy.

ABSTRACT:

Background

Subcutaneous immunotherapy has emerged as an effective option for treating allergic diseases. Here, we assessed the clinical impact of the mannan-conjugated birch pollen polymerized allergoid T502 in birch pollen-induced allergic rhinoconjunctivitis.

Methods

In this prospective, randomized, double-blind placebo-controlled phase III trial, 298 birch pollen-allergic adult patients were treated across 28 trial sites in Germany. Patients received either placebo or 23,000 mTU T502 subcutaneously over five pre-seasonal visits. Efficacy was assessed by comparing the combined symptom and medication score (CSMS) between placebo and T502 during the peak birch pollen season 2022. Safety, tolerability and immunologic effects were also analyzed.

Results

During the peak

SUBMITTER: Mosges R 

PROVIDER: S-EPMC11891431 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature